We are proud and pleased to have received the award for the Best Market Data Service at the Systems in the City Fintech Awards during an online ceremony hosted on 10th September 2020. In addition, Ricky Strachan, Sales Manager at Infront in the UK, received an award for Sales Manager of the Year.
Who is the new Infront and what does it stand for?
Read the following interview about our new market positioning, our product strategy and how you will benefit from it. Kristian Nesbak, CEO of Infront, Florent Grauer as CPO of Infront and Afsheen Azam as Head of Customer Support, Europe at Infront will give you some insights.
Infront announced today that Ramsey Crookall, the Isle of Man’s longest-established independent stockbroker, has gone live with the Infront Professional Terminal, replacing their existing terminals across their trading and analyst desks.
We cordially invite you to the webinar "Customer Account | Postbox, Portfolio Access" on Tuesday, October 06, 2020 from 11:00 to 12:00. The event will be held in German language, please contact us, if you’re interested in an English version.
Customer Account is the digital solution for your customers:
An introduction is followed by live demonstrations and an overview of all available variants including a sneak preview of further development. Afterwards, we will of course be available to answer your questions.
Here you can register for the free webinar.
AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.
The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.
At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.
Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.
Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.
As in previous years, COPS invites to their annual COPS user meeting this year from 24 to 25 June 2021 at the Seehotel Rust in Rust on Neusiedlersee.
The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.
As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.
You can find further information here...
The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.
Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!
October 27, 2020
Further information will be available shortly here or under Quantalys Inside 2020.
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2021 website.
24.09.2020 BUSINESS WIRE: Aera Technology gibt auf Global Customer Summit allgemeine Veröffentlichung seines Cognitive Operating System™ bekannt.
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Erhöhte Agilität in Zeiten der Disruption ist entscheidend für Lieferkettenentscheidungen MOUNTAIN VIEW, Kalifornien --(BUSINESS WIRE)-- 24.09.2020 --Aera Technology hat heute die allgemeine Verfügbarkeit des Aera...
24.09.2020 BUSINESS WIRE: Kioxia erhält den Imperial Invention Prize (kaiserlicher Erfindungspreis) der National Commendation for Invention 2020
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.TOKIO --(BUSINESS WIRE)-- 24.09.2020 --Die Kioxia Corporation, ein weltweit führender Anbieter von Speicherlösungen, gab heute bekannt, dass das Unternehmen für seine Erfindung eines 3D-Flash-Speicherbausteins hoher...
24.09.2020 BUSINESS WIRE: DXC-Technologie ernennt Führungskräfte zur Unterstützung des „neuen DXC“
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.TYSONS, Virginia, USA --(BUSINESS WIRE)-- 24.09.2020 --DXC Technology (NYSE:DXC) stellte heute seine jüngsten Ernennungen für Führungspositionen vor, die das DXC-Führungsteam weiter stärken werden. Die meisten von...
24.09.2020 BUSINESS WIRE: Science, Data, and Facts Should Unite Decision-Making, Says PMI CEO in Speech at Concordia Summit
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.LAUSANNE, Switzerland --(BUSINESS WIRE)-- 24.09.2020 --André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit. Calantzopoulos...
24.09.2020 BUSINESS WIRE: NanoTemper Technologies veröffentlicht DLS-Funktion bei Prometheus Panta und ermöglicht so hochauflösende, bereichsspezifische Stabilitätscharakterisierungen für Biologika
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Prometheus, der neue Goldstandard, sorgt jetzt für Klarheit bei den anspruchsvollsten StabilitätscharakterisierungenSOUTH SAN FRANCISCO, Kalifornien --(BUSINESS WIRE)-- 24.09.2020 --NanoTemper Technologies, bekannt...
24.09.2020 BUSINESS WIRE: Swiss Medical Group Holding übernimmt CoreMedica Europe
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.LUXEMBURG --(BUSINESS WIRE)-- 24.09.2020 --Die Swiss Medical Group (SMG) Holding Luxembourg SA, die für die Entwicklung von STARKS Age-Management in Europa und Asien massgeblich verantwortlich ist, gab die Übernahme...
19.09.2020 Mynewsdesk: #UnserHerzFürDieWiesn - Ein Gruß der Münchner Brauereien und der Oktoberfest-Familie in die Welt
Böllerschüsse und das „Ozapft is“ des Münchner Oberbürgermeister läuten normalerweise das Oktoberfest ein – nicht so 2020. Auf Initiative der Paulaner Brauerei, eine der sechs Münchner Traditionsbrauereien, die auf dem Oktoberfest ihr Bier ...
16.09.2020 Mynewsdesk: Welttag der Patientensicherheit 2020: VOD fordert Berufsgesetz für Osteopathen zum Schutz der Patienten
Eine berufsgesetzliche Regelung der Ausbildung und Ausübung fordert der Verband der Osteopathen Deutschland (VOD) e.V. anlässlich des Welttages der Patientensicherheit am 17. September 2020.Laut einer Forsa-Umfrage waren bereits rund 12 Millionen Bundesbürger in osteopathischer ...
15.09.2020 Mynewsdesk: Woche des Hörens 2020 vom 21. bis 26. September - Hören ist individuell!
FGH, 2020. – Die Einzigartigkeit des menschlichen Hörens steht im Mittelpunkt der diesjährigen Aktionswoche zur Hörgesundheit in Deutschland. Denn der Hörsinn ist so individuell wie ein Fingerabdruck. Jeder Mensch hört ein wenig anders und stellt deshalb auch ganz ...
11.09.2020 Mynewsdesk: Caravan Salon auf Messe.TV
Ob Wohnwagen oder Wohnmobil, für immer mehr Urlauber geht es mit dem eigenen Hotel auf die Reise. Die Reise- und Tourismusbranche sind von Corona und auch den damit einhergehenden politischen Maßnahmen schwer betroffen. Doch im Gegensatz zu anderen Bereichen geht ...
10.09.2020 Mynewsdesk: Starke Männer - starke Osteopathie / Verband der Osteopathen Deutschland (VOD) e.V.: 'Weltmeisterliche, abenteuerliche und atemberaubende Höchstleitungen'
Handwerker-Profis, Wüsten-Rallye-Fahrer und Fallschirmspringer-Asse schwören auf Osteopathie. Denn auch wenn man zuerst nicht daran denken würde: Gerade Männer mit Berufen und Hobbies mit starker körperlicher Beanspruchung minimieren Belastungen und rufen ...
02.09.2020 Mynewsdesk: Verband des Jahres 2020: BdS erhält Auszeichnung von der Deutschen Gesellschaft für Verbandsmanagement
Beim diesjährigen 17. Deutschen Verbändekongress der Deutschen Gesellschaft für Verbandsmanagement e.V. (DGVM): https://www.dgvm.de/, der am 1. und 2. September in Berlin stattfand, wurde der Bundesverband der Systemgastronomie e. V. als „Verband des Jahres 2020“ in der ...
06.08.2020 GlobeNewswire: Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing
Idorsia Japan confirms daridorexant dose response in Japanese patients with
insomnia – preparation for a local registration program advancing
Allschwil, Switzerland, and Tokyo, Japan – August 6, 2020
Idorsia Ltd (SIX: IDIA), Idorsia Pharmaceuticals Japan today announced the
positive conclusion of a dose-confirmation study for daridorexant, Idorsia’s
dual orexin receptor antagonist, in Japanese patients with insomnia. On the
basis of the positive results, preparation of registration studies in Japan is
The Phase 2 study was a multicenter, double-blind, randomized,
placebo-controlled, 4-period, 4-treatment crossover polysomnography dose
response study to investigate the efficacy and safety of daridorexant on the
first 2 days of each treatment period in Japanese patients with insomnia. In
addition, the 4 th double-blind treatment period was followed by a treatment
duration of 12 days to investigate subjective efficacy variables and safety
Treatment with daridorexant in 47 adult patients (ranging from 16 to 64 years)
showed a significant dose-dependent decrease in WASO at Day 1 & 2 (average
decrease of wake time after sleep onset from baseline on the 2 nights of
treatment, measured by polysomnography). In addition, daridorexant
significantly decreased LPS (latency to persistent sleep) in a dose-dependent
manner. Furthermore, daridorexant showed significant improvements on subjective
sleep parameters such as sWASO (subjective wake after sleep onset), sLSO
(subjective latency to sleep onset) and sTST (subjective total sleep time).
Treatment with daridorexant was generally well tolerated. Most of the adverse
events were mild. There were no reports of serious adverse events and
withdrawals related to daridorexant.
Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented:
“Our Japanese team, under the leadership of Dr Satoshi Tanaka, has done an
outstanding job to advance the development of daridorexant for Japanese
patients so rapidly. The results we see in this Phase 2 dose-confirmation
study, extend the excellent profile of daridorexant seen in two large pivotal
global studies to a Japanese population. This will enable initiation of the
registration study in Japan so that Japanese patients can benefit from
daridorexant as soon as possible.”
Dr Satoshi Tanaka, President of Idorsia Pharmaceuticals Japan, commented:
“It is very satisfying to see the results of the first randomized trial run by
the Idorsia team in Japan. The team has delivered robust, high-quality data
which clearly support the development of daridorexant for Japanese patients
with insomnia. We are now working very hard with our partner Mochida to prepare
for the Phase 3 registration studies in Japan.”
In April and July 2020, Idorsia reported positive results in each of the two
pivotal Phase 3 studies of daridorexant in patients with insomnia. The program
demonstrated efficacy of treatment with daridorexant on objective and
subjective sleep parameters, and daytime functioning, with patients reporting
no morning sleepiness, and no evidence of rebound or withdrawal symptoms upon
treatment discontinuation. More details and commentary can be found in the
dedicated press releases ( first study ), ( second study ) and the investor
webcasts ( first study ), ( second study ) which are available for replay on
the corporate website.
In December 2019, Idorsia and Mochida Pharmaceutical Co., Ltd. entered into an
exclusive license agreement for the supply, co-development and co-marketing of
daridorexant for insomnia and related disorders in Japan.
Notes to the editor
Insomnia is a condition of overactive wake signaling that can have a profound
effect on the lives of patients. Insomnia can be defined as difficulty falling
asleep and / or staying asleep, occuring at least three times a week for a
minimum of three months.
It is estimated that as many as one in ten people suffer from insomnia and its
impact is often underestimated. In reality, it can be a distressing condition
that can impair quality of life. Sleepless nights can leave people feeling
irritable and out of sorts – this may affect many aspects of daily life, from
studying and employment to social activities and relationships. People who
suffer from insomnia may lack the energy or motivation to exercise or to take
part in social activities. It can also have a significant economic impact as it
increases the risk of accident and injury on the road or in the workplace, and
is a leading cause of absenteeism and reduced productivity at work. People with
insomnia are more likely to experience feeling down or depressed, lack
concentration, and suffer from poor energy levels during the day compared with
people who sleep well. In addition, worrying about sleep can cause stress and
may lead to negative thought patterns which may in turn make it more difficult
to sleep, setting up a vicious circle. Chronic insomnia is associated with
cardiovascular and cerebrovascular diseases, and increased mortality.
The goal of treatments for insomnia is to improve sleep quality and quantity,
as well as reducing insomnia-related impaired daytime functioning, while
avoiding adverse events and next morning residual effect. Current treatment of
insomnia includes cognitive behavioral therapy, sleep hygiene recommendations,
and pharmacotherapy. The most widely prescribed products on the market that are
indicated for insomnia enhance the effects of gamma-aminobutyric acid (GABA),
the major inhibitory neurotransmitter in the central nervous system. Such
medications are only approved for short-term use and are associated with side
effects such as next-morning residual effects, anterograde amnesia, and risk of
tolerance and dependence.
About the orexin system
Wake and sleep signaling is regulated by intricate neural circuitry in the
brain. One key component of this process is the orexin system, which helps
promote and consolidate wakefulness. There are two forms of orexin
neuropeptides – Orexin A and Orexin B. Orexin promotes wakefulness through its
receptors OX 1 R and OX 2 R. In combination, these neuropeptides and receptors
comprise the orexin system. The orexin system stimulates target neurons in the
wake system – leading to the release of several chemicals (Dopamine, Serotonin,
Histamine, Acetylcholine, Norepinephrine) which promote wakefulness. Under
normal circumstances, orexin levels rise throughout the day as wakefulness is
promoted and then consolidated and fall at night. Overactivity of the orexin
system is thought to be an important driver of insomnia.
Idorsia’s research team has been working on the science of orexin and orexin
receptors since they were first described in 1998. The teams initial work led
to the conclusion that antagonism of the orexin system was the key to
preserving a natural sleep architecture for patients with insomnia. With this
as the target the team started to design a dual antagonist with a rapid effect,
and a duration of action sufficient for the night but short enough to avoid any
negative residual activity the following morning at optimally effective doses.
About dual orexin receptor antagonism
Dual orexin receptor antagonists – or DORAs – are an entirely different
approach to treating insomnia than previous drug classes, turning down
overactive wakefulness by blocking the activity of orexin. DORAs specifically
target the orexin system by competitively binding with both receptors and
thereby reversibly blocking the activity of orexin. It is hypothesized that
blocking orexin receptors reduces the downstream activity of the other wake
promoting neurotransmitters that are overactive in insomnia, leading to the
clinical efficacy demonstrated by orexin receptor antagonists.
References Dauvilliers, Y., et al. (2020). Ann Neurol 87(3): 347-356. Zammit,
G., et al. (2020). Neurology 94(21): e2222-e2232. Muehlan, C., et al. (2020). J
Clin Psychopharmacol 40(2): 157-166. Muehlan, C., et al. (2020). J
Psychopharmacol 34(3): 326-335. Boof, M. L., et al. (2019). Eur J Clin
Pharmacol 75(2): 195-205. Muehlan, C., et al. (2019). Curr Drug Metab 20(4):
254-265. Muehlan, C., et al. (2019). Eur Neuropsychopharmacol 29(7): 847-857.
Muehlan, C., et al. (2018). Clin Pharmacol Ther 104(5): 1022-1029. Treiber, A.,
et al. (2017). J Pharmacol Exp Ther 362(3): 489-503.
Mochida Pharmaceutical Co., Ltd. has been committed to research and
development of innovative pharmaceutical products since its establishment
thereby providing distinctive medicines to the medical field. Currently, the
core pharmaceutical business focuses resources on the targeted areas of
cardiovascular medicine, obstetrics and gynecology, dermatology, psychiatry and
gastroenterology, while also providing medicine for intractable disease as well
as generics including biosimilars, to meet medical needs. For more information
on Mochida Pharmaceutical Co., Ltd., please see www.mochida.co.jp
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into one of Europe’s leading biopharmaceutical companies,
with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is
specialized in the discovery and development of small molecules, to transform
the horizon of therapeutic options. Idorsia has a broad portfolio of innovative
drugs in the pipeline, an experienced team, a fully-functional research center,
and a strong balance sheet – the ideal constellation to bringing R&D efforts to
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 800 highly qualified specialists dedicated to realizing our
Idorsia Pharmaceuticals Japan was established, under the leadership of Dr
Satoshi Tanaka, in 2018 to conduct clinical development and prepare the
commercialization of Idorsia's innovative and promising compounds for patients
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF